Company / EPS (Diluted)
Aclaris Therapeutics, Inc. EPS (Diluted) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.71
FY2025
5-year range
-$3.90 / -$1.20
FY2021-FY2025
Trend
-34.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) has fluctuated over the past 9 years, ranging from $-4.03 in FY2020 to $-1.20 in FY2022.
Based on SEC 10-K filings.
-1.71 in FY2025.
Declined from $-1.60 to $-1.71 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 34.6% year-over-year.
- Peak eps (diluted) was recorded in FY2022.
- Lowest eps (diluted) in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.71 | -34.6% |
| FY2024 | -$1.27 | +20.6% |
| FY2023 | -$1.60 | -33.3% |
| FY2022 | -$1.20 | +69.2% |
| FY2021 | -$3.90 | +3.2% |
| FY2020 | -$4.03 | -65.2% |
| FY2019 | -$2.44 | -8.4% |
| FY2018 | -$2.25 | +40.6% |
| FY2017 | -$3.79 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026